login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ACCOLADE INC (ACCD) Stock News
USA
- NASDAQ:ACCD -
US00437E1029
-
Common Stock
7.02
USD
-0.01 (-0.14%)
Last: 4/7/2025, 8:11:12 PM
7.02
USD
0 (0%)
After Hours:
4/7/2025, 8:11:12 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ACCD Latest News, Press Relases and Analysis
All
Press Releases
6 months ago - By: Accolade, Inc.
Accolade Stockholders Approve Merger Between Accolade and Transcarent
7 months ago - By: Benzinga
- Mentions:
EXAS
IRDM
TEM
ARKQ
...
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
7 months ago - By: Halper Sadeh LLC
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders
7 months ago - By: Accolade, Inc.
Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction
8 months ago - By: Rowley Law PLLC
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade
8 months ago - By: Benzinga
Accolade Q3 Earnings Assessment
7 months ago - By: Halper Sadeh LLC
- Mentions:
ENFN
FNA
LGTY
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, FNA, LGTY, ACCD on Behalf of Shareholders
7 months ago - By: Brodsky & Smith LLC
- Mentions:
FNA
LGTY
ENFN
CWAN
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Accolade, Inc. (Nasdaq - ACCD), Paragon 28, Inc. (NYSE - FNA), Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN)
9 months ago - By: Accolade, Inc.
Transcarent To Acquire Accolade
8 months ago - By: Brodsky & Smith LLC
- Mentions:
ENFN
ITCI
PYCR
CWAN
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
8 months ago - By: Halper Sadeh LLC
- Mentions:
SSTK
ESSA
AKYA
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of Shareholders
9 months ago - By: Kahn Swick & Foti, LLC
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD
9 months ago - By: Ademi LLP
Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders
9 months ago - By: Halper Sadeh LLC
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders
9 months ago - By: Transcarent
Transcarent To Acquire Accolade
9 months ago - By: Accolade, Inc.
Transcarent To Acquire Accolade
9 months ago - By: Accolade, Inc.
Accolade to Announce Fiscal Third Quarter 2025 Financial Results
10 months ago - By: Accolade, Inc.
Accolade To Present at Upcoming Investor Conferences
a year ago - By: Accolade, Inc.
Accolade Announces Results for Fiscal Second Quarter 2025
a year ago - By: Accolade, Inc.
Accolade Announces Results for Fiscal Second Quarter 2025
Please enable JavaScript to continue using this application.